Historic clinical trial data represent a valuable and, until now, relatively untapped resource that could accelerate research and development of new drugs.
The quick uptake of tailored therapies by stakeholders in Europe offers the opportunity to propel the Continent ahead of the US to reap commercial success, believes Jurgi Camblong.